06-	. 19 - 03	:3754
CERTIFICATE OF MAILING BY "EXPRESS I Applicant(s): WILLIAMS, Geralt	MAIL" (37 CFR 1.1ช)	Docket No. PX3904USW
Serial No. JUN 1 8 2003 Filing Date 09/647,405 Jamiary 26, 2001	Examiner K. Bomberg	Group Art Unit 3754
Invention: METERING TO E		
{		RECEIVED
	·	JUN 2 4 2003 TECHNOLOGY CENTER R3700
I hereby certify that this IDS w/references (15-21 on D	(Identify type of correspondence)	
is being deposited with the United States Postal Servi		
37 CFR 1.10 in an envelope addressed to: Director of 1450, Alexandria, VA 22313-1450 on	the United States Patent and 18, 2003 (Date)	d Trademark Office, P.O. Box
	Joyce Ha	
	(Typed or Printed Name of Person Mail	mett ling Correspondence)
Lagrange of the second of the	the Carticology of the Carticolo	

THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED

In reapplication of: WILLIAMS, Geralt

Serial No.: 09/647,405

Group Art Unit: 3754

Examiner: Kenneth Bomberg

JUN 24 2003

TECHNOLOGY CENTER R3700

Appln. Filed: January 26, 2001

For: METERING VALVE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

		f the references are enclosed (References 15-21 are on CD Disk and 22 & 23 are attached as	
·	[] A copy	f the references were submitted in parent application Serial No (37 CFR 1.98(d)) f the International Search Report, which issued on International Application No is submitted herewith. All of the publications cited in the International Search Report are listed tached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. ffice by the International Bureau.	:d
A.	[]	The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an internationa application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).	
	OR		
		The Information Disclosure Statement submitted herewith is being filed before the mailin of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).	g
В.	(2)	The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either: a final action under § 1.113 or a notice of allowance under § 1.311, er occurs first.	
	Sta	licant hereby certifies that each item of information contained in this Information Disclosure ement was cited in a communication from a foreign patent office in a counterpart foreign ication not more than three months prior to the filing of this statement.	
		cant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information of Statement under § 1.97(c) (\$180.00).	n
TEVEDVEDOS MELANCI	0 60000011 0	1392 09647405	
20 2 0 31003	100.00 58		

Express Mail Label No. EV332143525US

30 F**0**s1008

C. []	The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.	
	In accordance with the requirements of 37 CFR 1.97(d):	
[]	[] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.	
[]	Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).	
[]	The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.	
[X] Please charge any required fees to Deposit Account No.07-1392.[X] A duplicate copy of this paper is attached.		
	Respectfully Submitted,	

V. Michael Strickland Registration No. 47,115

GlaxoSmithKline

Corporate Intellectual Property Five Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709

Telephone: (919) 483-9024 Facsimile: (919) 483-7988